Lipoprotein(a) is a feature of the presence, diffuseness, and severity of coronary artery disease in Saudi population

Saudi Medical Journal

Volumn 30, Issue 3, 2009, Pages 346-352

  Habib, Syed S ^a   Abdel Gader, Abdel Galil M ^a   Kurdi, Mohammad I ^a   Al Aseri, Zohair ^a   Soliman, Mona M ^a  

^a KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD SAMPLING; BODY MASS; CIGARETTE SMOKING; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DIABETES MELLITUS; DISEASE SEVERITY; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PREDICTION; SAUDI ARABIA; SCORING SYSTEM; ANALYSIS OF VARIANCE; BLOOD; CASE CONTROL STUDY; CROSS-SECTIONAL STUDY; HOSPITALIZATION; MIDDLE AGED; NONPARAMETRIC TEST; RADIOGRAPHY; STATISTICAL MODEL;

ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LIPOPROTEIN(A); LOGISTIC MODELS; MALE; MIDDLE AGED; SAUDI ARABIA; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TRIGLYCERIDES;

EID: 67649203991     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Danesh J, Collins R, Peto. Lipoprotein(a) and coronary heart disease: A meta-anlysis of prospective studies. Circulation 2000; 102: 1082-1085.
2. von Eckardstein A, Schulte H, Cullen P, Assmann G. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol 2001; 37: 343-349.
3. Luc G, Bard JM, Arveiler D, Ferrieres J, Evans A, Amouyel P, et al. Lipoprotein(a) as a predictor of coronary heart disease: The PRIME study. Atherosclerosis 2002; 163: 377-384.
4. Utermann G. The mysteries of lipoprotein(a). Science 1989; 246: 904-910.
5. Wang W, Lee ET, Alaupovic P, Blackett P, Blevins KS. Correlation between Lipoprotein(a) and Other Risk Factors for Cardiovascular Disease and Diabetes in Cherokee Indians: The Cherokee Diabetes Study. Ann Epidemiol 2005; 15: 390-397.
6. Stubbs P, Seed M, Lane D, Collinson P, Kendall F, Noble M. Lipoprotein(a) as a risk predictor for cardiac mortality in patients with acute coronary syndromes. Eur Heart J 1998; 19: 1355-1364.
7. Glader CA, Birgander LS, Stenlund H, Dahlen GH, Is lipoprotein(a) a predictor for survival in patients with established coronary artery disease? Results from a prospective patient cohort study in northern Sweden. J Intern Med 2002; 252: 27-35.
8. Zairis MN, Ambrose JA, Manousakis SJ, Stefanidis AS, Papadaki OA, Bilianou HI et al. The impact of plasma levels of C-reactive protein, lipoprotein(a) and homocysteine on the long-term prognosis after successful coronary stenting: The Global Evaluation of New Events and Restenosis After Stent Implantation Study. J Am Coll Cardiol 2002; 40: 1375-1382.
9. Shlipak MG, Simon JA, Vittinghoff E, Lin F, Barrett-Connor E, Knopp RH et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA. 2000; 283: 1845-1852.
10. Lundstam U, Herlitz J, Karlsson T, Linden T, Wiklund O. Serum lipids, lipoprotein(a) level, and apolipoprotein(a) isoforms as prognostic markers in patients with coronary heart disease. J Intern Med 2002; 251: 111-118.
11. Skinner JS, Farrer M, Albers CJ, Piper K, Neil HA, Adams PC. Seru, Lp(a) lipoprotein concentration is not associated with clinical and angiographic outcome five years after coronary artery bypass graft surgery. Heart 1997; 78: 131-135.
12. Linden T, Taddei-Peters W, Wilhelmsen L, Herlitz J, Karlsson T, Ullstrom C et al. Serum lipids, lipoprotein(a) and apo(a)a isoforms in patients with established coronary artery disease and their relation to disease and prognosis after coronary bypass surgery. Atherosclerosis 1998; 137: 175-186.
13. Auer J, Rammer M, Berent R, Weber T, Lassnig E, Eber B. Lack of association between plasma lipoprotein(a) concentrations and the presence or absence of coronary atherosclerosis. Acta Cardiol 2002; 57: 409-414.
14. Rasouli M, Kiasari AM, Mokhberi V. The ratio of apoB/apoAI, apoB and lipoprotein(a) are the best predictors of stable coronary artery disease. Clin Chem Lab Med 2006; 44: 1015-1021.
15. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
16. Pahor M, Elam MB, Garrison RJ, Kritchevsky SB, Applegate WB. Emerging noninvasive biochemical measures to predict cardiovascular risk. Arch Intern Med 1999; 159: 237-245.
17. Kostner KM. Kostner GM. Lipoprotein (a): Still an enigma? Curr Opin Lipidol 2002; 13: 391-396.
18. Farish E, Rolton HA, Barnes JF, Hart DM. Lipoprotein (a) concentrations in postmenopausal women taking nonrethisterone. BMJ 1991; 303: 694.
19. Dati F, Tate JR, Marcovina SM, Steinmetz A; First WHO/IFCC International Reference Reagent for Lipoprotein(a) for Immunoassay - Lp(a) SRM 2B. Clin Chem Lab Med 2004; 42: 670-66.
20. Gensini GG, A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardio 1983; 51: 606.
21. Uusimaa P, Kervinen K, Kesäniemi A, Peukurinen K. Serum lipoprotein(a) level in relation to severity of coronary artery disease and coronary artery patency in acute myocardial infarction. Heart Vessels 2002; 16: 37-341.
22. Lima LM, Carvalho MG, Loures-Vale AA, Fernandes AP, Mota AP, Neto CP, et al. Increased serum levels of lipoprotein(a) correlated with the severity of coronary artery disease in patients submitted to angiography. Arq Bras Cardiol 2006; 87: 260-266.
23. Habib SS, Aslam M. Lipids and lipoprotein(a) concentrations in Pakistani patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 2004; 6: 338-343.
24. Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 1995; 274: 1771-1774.
25. Watts G, Gwilyn RMAP, Mazurkiewicz J, Coltard J. Independent correlation between plasma lipoprotein(a) and angiographic coronary artery disease in NIDDM. Diabetes Care 1995; 18: 234-236.
26. Okada E, Oida K, Tada H, Asazuma K, Eguchi K, Tohda G, et al. Hyperhomocysteinemia is a risk factor for coronary arteriosclerosis in Japanese patients with type 2 diabetes. Diabetes Care 1999; 22: 484-490.
27. Pedreno J, Fernandez R, Ballester A, Jornet A, Uson M, Canela J, et al. Lack of association of serum lipoprotein(a) levels with type 2 diabetes mellitus in patients with angiographically define coronary artery disease. Int J Cardiol 2000; 74: 159-167.
28. Zlatohlávek L, Zídková M, Prusíková M, Svobodová H, et al. Lipoprotein (a) and its position among other risk factors of atherosclerosis. Physiol Res 2008; 57: 777-783.
29. Zorio E, Falco C, Arnau MA, España F, Osa A, Ramon LA, et al. Lipoprotein(a) in young individuals as a marker of the presence of ischemic heart disease and the severity of coronary lesions. Haematologica 2006; 91: 562-565.
30. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005; 353: 46-57.
31. Gazzaruso C, Bruno R, Pujia A, De Amici E, Fratino P, Solerte SB, Garzaniti A. Lipoprotein(a). apoliprotein(a) polymorphism and coronary atherosclerosis severity in type 2 diabetic patients. Int J Cardiol 2006; 108: 354-358.
32. Jelaković B, Lagalnović M, Kuzmanić D. Lipoprotein (a) - a mysterious factor in Atherogenesis. Lijec Vjesn 2002; 124: 366-371.
33. Marcovina SM, Koschinsky ML. Lipoprotein(a) concentration and apolipoprotein(a) size: A synergistic role in advanced atherosclerosis? Circulation 1999; 100: 1151-1153.